This is Part 2 of 5 in the “The Weight of Empire: Novo Nordisk’s Fight for Survival” series.
The email arrived at 6:47 a.m. on a Tuesday, before most employees had finished their first cup of coffee. By 6:48 a.m., Lars Fruergaard Jorgensen was no longer the CEO of Novo Nordisk. By 6:49 a.m., nine thousand people had begun their countdown toward unemployment, though they did not know it yet.
The press release was three paragraphs long. It thanked Jorgensen for his eight years of leadership. It praised his “commitment to patients and scientific excellence.” It announced that the board, “in consultation with the Novo Nordisk Foundation,” had initiated a leadership transition and would name a new CEO following a “focused search process.” The language was warm and bureaucratic and entirely bloodless, which is how Danish corporations preferred to conduct their executions.
Jorgensen learned of his removal the evening before, in a call from Helge Lund that lasted eleven minutes. Lund spoke in the same careful, neutral tone he used for everything, as though he were discussing a quarterly forecast rather than ending a man’s career. The Foundation, Lund explained, had concluded that the company needed a different kind of leadership for the next phase. It was not a reflection of Jorgensen’s abilities. It was a matter of fit.
“Lars,” Jorgensen said – meaning Sorensen, the other Lars, the Lars who actually made the decisions – “this is Lars, isn’t it?”
Lund paused. “The Foundation and the board are aligned on this.”
It was the most dishonest thing Helge Lund had ever said, and both men knew it.
The search for a replacement was announced as an external process. It was, in reality, a formality. Lars Rebien Sorensen had identified his candidate months before Jorgensen’s departure was finalized.
Mike Doustdar was fifty-three years old, Iranian-born, British-educated, and had spent the last two decades climbing through Novo Nordisk’s commercial operations. He had run the company’s international business, overseeing market launches across Asia, the Middle East, and Latin America. He was fluent in five languages. He had a reputation for relentless execution, an almost obsessive attention to sales data, and the kind of energy that made quieter colleagues feel exhausted just sitting in the same room.
What he did not have was experience running a $400 billion company. He had never managed a global R&D organization. He had never navigated a governance crisis, a regulatory showdown, or a competitive war at this scale. He had been chosen not despite these gaps but, in a sense, because of them. Sorensen did not want a CEO who would challenge the Foundation’s strategic vision. He wanted one who would execute it.
Doustdar accepted the role on a Friday afternoon in late July and began officially on the first Monday of August. He arrived at Bagsvaerd headquarters at 6:15 a.m., thirty minutes before the security guards expected him. The corner office – Jorgensen’s old office – had been repainted over the weekend. The construction cranes were still visible from the window, though two of them had stopped moving.
His first meeting was with the chief financial officer. His second was with the head of human resources. His third was with Lars Rebien Sorensen, who arrived at ten o’clock carrying a single folder and a calm expression that did not change for the next ninety minutes.
“The company is overstaffed by at least ten percent,” Sorensen said. “Lars let the headcount grow because the revenue was growing faster. That is no longer the case.”
Doustdar looked at the numbers in the folder. The projections showed what would happen to margins if Novo Nordisk continued at its current cost structure while losing market share to Eli Lilly and absorbing potential pricing pressure from the U.S. government. The lines on the graph crossed in a way that left no room for interpretation.
“How fast?” Doustdar asked.
“Announce by September. Execute by year-end.”
“How many?”
“Nine thousand. At minimum.”
Doustdar closed the folder. He had known this was coming – the restructuring had been part of the informal understanding that preceded his appointment. But seeing the number on paper, written in Sorensen’s precise hand at the bottom of the final page, gave it a weight that conversation had not.
Nine thousand people. Eleven and a half percent of the workforce. Five thousand of them in Denmark.
“The unions will go to the press,” Doustdar said.
“The unions will do what unions do. The press will write what the press writes. And then the market will decide whether we acted quickly enough.”
The announcement came in September, and Denmark reacted as though it had been struck.
This was not a factory closing in some forgotten provincial town. This was Novo Nordisk – the company that had transformed Denmark from a small northern European nation into a global pharmaceutical powerhouse. The company that accounted for roughly 3% of Danish GDP. The company whose campus in Bagsvaerd was a national landmark, whose research labs in Malov attracted scientists from around the world, whose manufacturing plants in Kalundborg and Hillerod employed entire communities.
Five thousand Danish jobs. The number dominated the front page of Politiken and Berlingske for three consecutive days. Television cameras appeared outside the Bagsvaerd gates, capturing the faces of employees arriving for shifts they were not certain they would finish. The Danish Minister of Employment issued a statement calling the layoffs “deeply concerning” and promising government support for affected workers. The Prime Minister, in a press conference about an unrelated matter, was asked whether Novo Nordisk was still a responsible corporate citizen. She chose her words with visible care.
In Kalundborg, where the massive semaglutide production facility employed thousands, the news hit with particular force. The plant had been expanding for years – new buildings, new production lines, a workforce that had doubled since 2020. Workers who had relocated their families to be closer to the facility now faced the possibility that their jobs would vanish before their mortgages were paid.
A production supervisor named Henrik, who had worked at the Kalundborg plant for fourteen years, described the atmosphere to a reporter from DR, the Danish public broadcaster. “It’s like being told your family is being restructured,” he said. “You know you should be professional about it. You know it’s business. But when you have given this company your weekdays and your weekends and your holidays for fourteen years, and they send you an email telling you that a ‘workforce optimization’ is under way – it doesn’t feel like business. It feels like betrayal.”
The separation packages were, by industry standards, generous. Six months of salary for employees with fewer than five years of service. Twelve months for those with more than ten. Career counseling. Extended health coverage. All of it designed by the HR department with the precision and impersonality of a military operation.
None of it accounted for the fact that in towns like Kalundborg and Hillerod, there was nowhere else to go. Novo Nordisk was not one employer among many. It was the employer. The other jobs – the restaurants, the childcare centers, the construction companies – existed because Novo Nordisk existed. When the company cut five thousand Danish workers, the secondary effects would ripple outward for years.
Doustdar handled the public communications himself. He appeared on Danish television, sat for interviews with Reuters and Bloomberg, and addressed the remaining employees in a series of town hall meetings that were streamed to every Novo Nordisk office in the world.
His message was consistent, delivered in the rapid, confident cadence that had made him effective on the commercial side of the business: the company was not in crisis. It was adapting. The restructuring was necessary to create a leaner, faster organization capable of competing in a market that had changed. The GLP-1 opportunity was still enormous. The pipeline was still strong. And the future – he used this word repeatedly, with an emphasis that suggested he believed it – the future was bright.
“I know this is painful,” he told the town hall audience in Bagsvaerd, standing on a stage without notes, his sleeves rolled to the elbows. “I know some of you are wondering whether this company still values the work you’ve done. I’m here to tell you that it does. But I’m also here to tell you the truth, which is that we cannot compete in 2026 with the cost structure of 2023. We have to change, and change means making choices that are difficult. I didn’t come here to make easy choices. I came here to make the right ones.”
The applause was thin. Polite, because this was Denmark, where people clapped for speakers even when they disagreed with them. But thin.
Afterward, in the corridor outside the auditorium, Doustdar’s chief of staff fell into step beside him.
“How do you think that went?”
Doustdar kept walking. “They don’t believe me yet. They’ll believe me when the numbers turn.”
“And if the numbers don’t turn?”
Doustdar glanced at her. “Then I’ll be giving a different kind of town hall.”
The analyst community was divided. Some saw the layoffs as a decisive first move – the kind of bold restructuring that signaled a new CEO understood the severity of the situation. J.P. Morgan upgraded the stock, writing that Doustdar’s “willingness to act quickly on cost structure suggests a leader who prioritizes execution over consensus.” Morgan Stanley was less impressed, noting that the layoffs addressed expenses but did nothing about the revenue problem. “You cannot cut your way to growth,” their note concluded. “And growth is what Novo Nordisk needs.”
The stock, which had already fallen twenty percent from its 2024 highs, steadied. It did not recover. The market was waiting – waiting for Doustdar to show that he could do more than cut costs. Waiting for CagriSema regulatory updates. Waiting for the quarterly numbers that would reveal whether Zepbound was stealing market share or merely growing the overall market.
Inside the company, the mood was something harder to quantify. The surviving employees – the eighty-seven thousand who still had jobs – went through their days with the particular alertness of people who have watched colleagues disappear and are not certain they won’t be next. Meetings were shorter. Emails were more carefully worded. The cafeterias at Bagsvaerd, which had once buzzed with the relaxed energy of a company that believed it was invincible, were quieter now. People ate faster and returned to their desks. The construction cranes outside the window kept turning, but they felt less like monuments and more like reminders of money being spent that might not come back.
Lars Fruergaard Jorgensen, for his part, disappeared. He did not give interviews. He did not issue statements. He did not post on LinkedIn. He simply left – walked out of the building he had run for eight years, drove home to his house in Gentofte, and closed the door. Those who knew him said he was angry but not surprised. He had seen it coming since March, since the board meeting where Helge Lund would not meet his eyes. What wounded him was not the removal itself but the fiction that surrounded it – the idea that this was a planned transition, a mutual decision, a natural evolution of leadership. It was none of those things. It was a power play by a Foundation chairman who believed he could run the company better through a proxy than Jorgensen could run it himself.
Whether Sorensen was right about that remained to be seen.
Three weeks into Doustdar’s tenure, on a Thursday evening when the Bagsvaerd campus was nearly empty, his phone rang. The caller was a former colleague who had moved to Washington to work in pharmaceutical policy. They had not spoken in months.
“Mike, I’m calling as a friend, not as a source. You need to know what’s coming.”
Doustdar sat down. “Tell me.”
“The administration is finalizing an executive order on prescription drug pricing. Most Favored Nation. They’re going to peg U.S. prices to the lowest price in a basket of reference countries.”
“That’s been talked about for years. It never happens.”
“It’s happening. The target list is short. Insulin. Oncology. And GLP-1 agonists. Wegovy and Ozempic are at the top.”
“What’s the target price?”
A pause. “I’ve heard three-fifty a month.”
Doustdar did the math instantly – it was the kind of calculation a commercial operator could perform without a spreadsheet. Wegovy’s list price was $1,349 per month. Ozempic was over $900. A forced reduction to $350 meant a margin collapse of more than sixty percent on the company’s two most important products. The layoffs he had just announced – the nine thousand jobs, the $1.3 billion in annual savings – would not come close to covering the gap.
“When?” he asked.
“Before Thanksgiving. They want it as a political win before the holiday news cycle.”
Doustdar thanked him, ended the call, and sat in the darkening office for a long time. Through the window, the construction cranes had stopped for the night. The parking lot was empty. The only light came from the security desk in the lobby, where a guard was reading something on his phone, unaware that the company he was paid to protect had just received a wound from which no restructuring plan, no matter how aggressive, could protect it.
The layoffs had been the first cut. The next one was already in the air, crossing the Atlantic, and there was nothing Mike Doustdar or Lars Rebien Sorensen or the entire Novo Nordisk Foundation could do to stop it.
This is a work of fiction. While inspired by real events and public information, all characters, dialogue, and internal deliberations are entirely imagined. Any resemblance to actual private conversations or decisions is coincidental.
